 Philip Zeitler
Concepts (587)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 77 | 2025 | 2512 | 7.820 |
Why?
| | Hypoglycemic Agents | 30 | 2024 | 1281 | 2.690 |
Why?
| | Puberty | 11 | 2021 | 146 | 2.220 |
Why?
| | Pediatric Obesity | 8 | 2021 | 590 | 2.030 |
Why?
| | Prediabetic State | 11 | 2024 | 253 | 2.010 |
Why?
| | Insulin Resistance | 20 | 2024 | 1201 | 1.880 |
Why?
| | Obesity | 32 | 2021 | 2975 | 1.810 |
Why?
| | Metformin | 17 | 2023 | 329 | 1.780 |
Why?
| | Adolescent | 103 | 2025 | 21463 | 1.680 |
Why?
| | Child | 94 | 2025 | 21968 | 1.400 |
Why?
| | Diabetes Complications | 5 | 2021 | 226 | 1.380 |
Why?
| | Glucose Tolerance Test | 13 | 2023 | 364 | 1.290 |
Why?
| | Blood Glucose | 30 | 2024 | 2180 | 1.250 |
Why?
| | Diabetes Mellitus, Type 1 | 15 | 2023 | 3709 | 1.130 |
Why?
| | Metabolic Syndrome | 10 | 2020 | 354 | 1.070 |
Why?
| | Klinefelter Syndrome | 6 | 2020 | 61 | 1.000 |
Why?
| | Growth Hormone-Releasing Hormone | 10 | 2006 | 24 | 0.990 |
Why?
| | Hypothyroidism | 3 | 2018 | 71 | 0.980 |
Why?
| | Life Style | 10 | 2016 | 484 | 0.960 |
Why?
| | Humans | 149 | 2025 | 136783 | 0.910 |
Why?
| | Body Weight | 6 | 2024 | 981 | 0.840 |
Why?
| | Treatment Failure | 4 | 2023 | 353 | 0.820 |
Why?
| | Muscular Dystrophy, Duchenne | 2 | 2025 | 90 | 0.780 |
Why?
| | Age of Onset | 10 | 2025 | 518 | 0.780 |
Why?
| | Mass Screening | 11 | 2022 | 1262 | 0.700 |
Why?
| | Endocrinologists | 1 | 2020 | 13 | 0.690 |
Why?
| | Thyroxine | 3 | 2014 | 62 | 0.680 |
Why?
| | Male | 85 | 2024 | 67361 | 0.660 |
Why?
| | Overweight | 4 | 2017 | 557 | 0.640 |
Why?
| | Glucocorticoids | 3 | 2025 | 596 | 0.640 |
Why?
| | Insulin | 12 | 2023 | 2399 | 0.620 |
Why?
| | Pediatricians | 1 | 2020 | 129 | 0.610 |
Why?
| | Risperidone | 1 | 2018 | 29 | 0.600 |
Why?
| | Adrenal Insufficiency | 1 | 2019 | 31 | 0.590 |
Why?
| | Neonatal Screening | 2 | 2018 | 169 | 0.590 |
Why?
| | Cardiovascular Diseases | 10 | 2020 | 2108 | 0.590 |
Why?
| | Osteoporosis | 4 | 2008 | 242 | 0.590 |
Why?
| | Neuromuscular Agents | 1 | 2019 | 35 | 0.580 |
Why?
| | Cystic Fibrosis | 7 | 2023 | 1104 | 0.580 |
Why?
| | Female | 84 | 2024 | 72840 | 0.580 |
Why?
| | Bariatric Surgery | 2 | 2018 | 214 | 0.580 |
Why?
| | Body Mass Index | 20 | 2021 | 2364 | 0.580 |
Why?
| | Fatty Liver | 4 | 2009 | 242 | 0.560 |
Why?
| | Health Services Needs and Demand | 2 | 2020 | 268 | 0.560 |
Why?
| | Diabetes Mellitus | 7 | 2022 | 1033 | 0.560 |
Why?
| | Insulin-Secreting Cells | 4 | 2021 | 372 | 0.550 |
Why?
| | Clinical Trials as Topic | 3 | 2019 | 1043 | 0.530 |
Why?
| | Sitagliptin Phosphate | 3 | 2021 | 33 | 0.520 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 116 | 0.500 |
Why?
| | Precision Medicine | 2 | 2020 | 426 | 0.460 |
Why?
| | Patient Education as Topic | 5 | 2015 | 760 | 0.460 |
Why?
| | Fructosamine | 4 | 2019 | 15 | 0.450 |
Why?
| | Incidence | 10 | 2023 | 2788 | 0.440 |
Why?
| | Glucose Intolerance | 3 | 2020 | 146 | 0.420 |
Why?
| | Serum Albumin | 4 | 2019 | 149 | 0.420 |
Why?
| | Hyperglycemic Hyperosmolar Nonketotic Coma | 2 | 2010 | 7 | 0.410 |
Why?
| | Risk Factors | 19 | 2022 | 10331 | 0.410 |
Why?
| | Deoxyglucose | 3 | 2019 | 52 | 0.400 |
Why?
| | Dyslipidemias | 2 | 2021 | 176 | 0.400 |
Why?
| | Adolescent Behavior | 2 | 2020 | 534 | 0.390 |
Why?
| | Hypothalamic Diseases | 2 | 2005 | 18 | 0.390 |
Why?
| | Congenital Hypothyroidism | 2 | 2018 | 11 | 0.390 |
Why?
| | Hypoglycemia | 3 | 2023 | 443 | 0.380 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2006 | 313 | 0.370 |
Why?
| | Self Care | 1 | 2014 | 375 | 0.360 |
Why?
| | Exercise Therapy | 3 | 2016 | 434 | 0.360 |
Why?
| | Prevalence | 10 | 2019 | 2712 | 0.350 |
Why?
| | Sex Chromosome Disorders | 1 | 2011 | 24 | 0.350 |
Why?
| | Digestion | 1 | 2010 | 10 | 0.340 |
Why?
| | Triglycerides | 4 | 2020 | 524 | 0.340 |
Why?
| | Colorado | 9 | 2020 | 4491 | 0.330 |
Why?
| | Weight Loss | 4 | 2017 | 775 | 0.330 |
Why?
| | Growth Hormone | 6 | 2005 | 101 | 0.330 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 738 | 0.330 |
Why?
| | Thyroid Hormones | 1 | 2010 | 61 | 0.330 |
Why?
| | Intestinal Absorption | 1 | 2010 | 101 | 0.330 |
Why?
| | Fractures, Bone | 2 | 2008 | 420 | 0.330 |
Why?
| | Receptors, Pituitary Hormone-Regulating Hormone | 5 | 2006 | 8 | 0.320 |
Why?
| | Receptors, Neuropeptide | 5 | 2006 | 12 | 0.320 |
Why?
| | Delivery of Health Care | 1 | 2016 | 939 | 0.310 |
Why?
| | Food | 1 | 2010 | 159 | 0.310 |
Why?
| | Absorptiometry, Photon | 2 | 2008 | 253 | 0.300 |
Why?
| | Double-Blind Method | 9 | 2023 | 1981 | 0.290 |
Why?
| | Testosterone | 5 | 2020 | 401 | 0.290 |
Why?
| | Patient Safety | 2 | 2021 | 304 | 0.290 |
Why?
| | Hypogonadism | 3 | 2016 | 88 | 0.290 |
Why?
| | Placental Lactogen | 6 | 1991 | 23 | 0.290 |
Why?
| | Fasting | 3 | 2020 | 278 | 0.290 |
Why?
| | Oxandrolone | 2 | 2018 | 8 | 0.280 |
Why?
| | Polycystic Ovary Syndrome | 2 | 2021 | 176 | 0.280 |
Why?
| | Diet, Diabetic | 1 | 2007 | 34 | 0.280 |
Why?
| | Reference Values | 5 | 2020 | 817 | 0.280 |
Why?
| | Adult | 20 | 2025 | 37616 | 0.280 |
Why?
| | Age Factors | 8 | 2020 | 3290 | 0.280 |
Why?
| | United States | 11 | 2023 | 14660 | 0.280 |
Why?
| | Risk | 3 | 2017 | 904 | 0.270 |
Why?
| | Thiazolidinediones | 3 | 2016 | 137 | 0.270 |
Why?
| | Diagnosis, Differential | 7 | 2014 | 1483 | 0.270 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2024 | 40 | 0.270 |
Why?
| | Blood Pressure | 4 | 2024 | 1772 | 0.270 |
Why?
| | Somatostatin | 5 | 2000 | 61 | 0.260 |
Why?
| | Dwarfism | 2 | 1998 | 17 | 0.260 |
Why?
| | Diphosphonates | 3 | 2007 | 66 | 0.260 |
Why?
| | Glucagon-Like Peptides | 2 | 2024 | 56 | 0.250 |
Why?
| | Biomarkers | 9 | 2023 | 4158 | 0.250 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2006 | 13 | 0.250 |
Why?
| | raf Kinases | 1 | 2006 | 13 | 0.250 |
Why?
| | Autocrine Communication | 1 | 2006 | 41 | 0.250 |
Why?
| | Alanine Transaminase | 2 | 2008 | 157 | 0.240 |
Why?
| | Paracrine Communication | 1 | 2006 | 65 | 0.240 |
Why?
| | Thyrotropin | 1 | 2006 | 114 | 0.240 |
Why?
| | Case-Control Studies | 11 | 2023 | 3537 | 0.240 |
Why?
| | ras Proteins | 1 | 2006 | 151 | 0.230 |
Why?
| | Treatment Outcome | 15 | 2023 | 10764 | 0.230 |
Why?
| | Pituitary Gland | 5 | 2000 | 149 | 0.230 |
Why?
| | Global Health | 2 | 2005 | 386 | 0.230 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5115 | 0.230 |
Why?
| | Growth Disorders | 2 | 2010 | 86 | 0.230 |
Why?
| | Arachidonic Acids | 5 | 1991 | 62 | 0.230 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 9 | 0.220 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 14 | 0.220 |
Why?
| | Recombinant Fusion Proteins | 2 | 2024 | 663 | 0.220 |
Why?
| | Comorbidity | 5 | 2013 | 1611 | 0.220 |
Why?
| | Proteinuria | 1 | 2024 | 97 | 0.220 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2018 | 607 | 0.220 |
Why?
| | Craniopharyngioma | 1 | 2005 | 74 | 0.220 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2013 | 37 | 0.220 |
Why?
| | Social Class | 2 | 2023 | 277 | 0.210 |
Why?
| | School Health Services | 1 | 2007 | 239 | 0.210 |
Why?
| | Body Composition | 5 | 2021 | 677 | 0.210 |
Why?
| | Hyperglycemia | 2 | 2018 | 346 | 0.210 |
Why?
| | Disease Management | 2 | 2019 | 623 | 0.210 |
Why?
| | Albuminuria | 1 | 2024 | 185 | 0.210 |
Why?
| | Risk Reduction Behavior | 3 | 2020 | 218 | 0.210 |
Why?
| | Cell Division | 2 | 2002 | 796 | 0.200 |
Why?
| | Pituitary Neoplasms | 1 | 2005 | 190 | 0.200 |
Why?
| | RNA, Messenger | 11 | 1998 | 2831 | 0.200 |
Why?
| | Longitudinal Studies | 3 | 2020 | 2847 | 0.200 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1281 | 0.200 |
Why?
| | Diabetic Ketoacidosis | 3 | 2007 | 202 | 0.200 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 45 | 0.200 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 93 | 0.200 |
Why?
| | Proinsulin | 1 | 2022 | 52 | 0.190 |
Why?
| | Breast Neoplasms | 2 | 2006 | 2239 | 0.190 |
Why?
| | Waist Circumference | 3 | 2020 | 143 | 0.180 |
Why?
| | Minority Groups | 2 | 2016 | 267 | 0.180 |
Why?
| | Family Health | 2 | 1999 | 197 | 0.180 |
Why?
| | Monitoring, Physiologic | 2 | 2022 | 267 | 0.180 |
Why?
| | Child, Preschool | 12 | 2018 | 11069 | 0.180 |
Why?
| | Disease Progression | 2 | 2020 | 2750 | 0.180 |
Why?
| | Smoking | 1 | 2009 | 1633 | 0.170 |
Why?
| | Sphenoid Sinus | 1 | 2000 | 11 | 0.170 |
Why?
| | Glomerular Filtration Rate | 1 | 2024 | 744 | 0.170 |
Why?
| | Sex Factors | 6 | 2019 | 2068 | 0.170 |
Why?
| | Nurses | 1 | 2003 | 173 | 0.170 |
Why?
| | Factor XII Deficiency | 1 | 1999 | 1 | 0.160 |
Why?
| | Young Adult | 12 | 2023 | 13126 | 0.160 |
Why?
| | Diabetes, Gestational | 2 | 2018 | 316 | 0.160 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 1999 | 29 | 0.160 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 596 | 0.160 |
Why?
| | Infant | 9 | 2014 | 9442 | 0.160 |
Why?
| | von Willebrand Diseases | 1 | 1999 | 27 | 0.160 |
Why?
| | Biomarkers, Pharmacological | 1 | 2019 | 28 | 0.160 |
Why?
| | Combined Modality Therapy | 3 | 2014 | 1235 | 0.160 |
Why?
| | Hyperphagia | 1 | 1999 | 33 | 0.160 |
Why?
| | Education | 1 | 2020 | 106 | 0.160 |
Why?
| | Body Height | 2 | 2018 | 199 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 495 | 0.160 |
Why?
| | Health Behavior | 2 | 2020 | 756 | 0.150 |
Why?
| | Puberty, Precocious | 1 | 2018 | 13 | 0.150 |
Why?
| | Blood Coagulation | 1 | 2001 | 253 | 0.150 |
Why?
| | Forecasting | 1 | 2020 | 384 | 0.150 |
Why?
| | Patient Compliance | 1 | 2003 | 576 | 0.150 |
Why?
| | Endocrine System Diseases | 1 | 1999 | 35 | 0.150 |
Why?
| | Hematologic Diseases | 1 | 1999 | 62 | 0.150 |
Why?
| | Phosphatidylinositols | 2 | 1991 | 57 | 0.150 |
Why?
| | Rats, Mutant Strains | 2 | 1998 | 25 | 0.150 |
Why?
| | Bone Diseases | 1 | 1999 | 62 | 0.150 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 140 | 0.150 |
Why?
| | Psychotropic Drugs | 1 | 2018 | 68 | 0.140 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 321 | 0.140 |
Why?
| | Thiazoles | 2 | 2016 | 123 | 0.140 |
Why?
| | Risk Management | 1 | 2019 | 91 | 0.140 |
Why?
| | Exome | 1 | 2019 | 231 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 2030 | 0.140 |
Why?
| | Cohort Studies | 8 | 2023 | 5718 | 0.140 |
Why?
| | Bone Density | 4 | 2009 | 487 | 0.140 |
Why?
| | Anthropometry | 4 | 2018 | 213 | 0.140 |
Why?
| | Pregnancy Complications | 2 | 2016 | 522 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2021 | 15564 | 0.140 |
Why?
| | Prognosis | 7 | 2020 | 4018 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1568 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 380 | 0.130 |
Why?
| | Androgens | 1 | 2018 | 187 | 0.130 |
Why?
| | Glycation End Products, Advanced | 4 | 2019 | 82 | 0.130 |
Why?
| | Sex Distribution | 3 | 2005 | 376 | 0.130 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 122 | 0.130 |
Why?
| | Interleukins | 1 | 2018 | 251 | 0.130 |
Why?
| | Transgender Persons | 1 | 2020 | 180 | 0.130 |
Why?
| | Antipsychotic Agents | 1 | 2018 | 192 | 0.130 |
Why?
| | Rats | 11 | 2000 | 5628 | 0.130 |
Why?
| | Allostasis | 1 | 2016 | 17 | 0.130 |
Why?
| | Diet Therapy | 1 | 2016 | 34 | 0.130 |
Why?
| | Hypothalamus | 3 | 1991 | 153 | 0.120 |
Why?
| | Population Surveillance | 1 | 2019 | 470 | 0.120 |
Why?
| | Social Control, Formal | 1 | 2015 | 11 | 0.120 |
Why?
| | Needs Assessment | 1 | 2018 | 369 | 0.120 |
Why?
| | Pregnancy | 11 | 2018 | 6731 | 0.120 |
Why?
| | Family | 2 | 2014 | 666 | 0.120 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 5417 | 0.120 |
Why?
| | Hypertension | 3 | 2021 | 1284 | 0.120 |
Why?
| | Societies, Medical | 2 | 2010 | 820 | 0.120 |
Why?
| | Women's Health | 1 | 2018 | 369 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 1157 | 0.110 |
Why?
| | Infant, Newborn | 4 | 2018 | 6046 | 0.110 |
Why?
| | Hemorrhage | 1 | 1999 | 723 | 0.110 |
Why?
| | Health Status | 2 | 2011 | 781 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 35 | 0.110 |
Why?
| | C-Peptide | 2 | 2023 | 163 | 0.110 |
Why?
| | Pediatrics | 3 | 2014 | 1112 | 0.110 |
Why?
| | Societies, Scientific | 1 | 2014 | 51 | 0.110 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 256 | 0.110 |
Why?
| | Software | 1 | 2019 | 663 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 36 | 0.110 |
Why?
| | Obesity, Morbid | 1 | 2018 | 258 | 0.110 |
Why?
| | Physicians | 1 | 2003 | 897 | 0.110 |
Why?
| | Quality Improvement | 1 | 2022 | 1152 | 0.110 |
Why?
| | Drug Therapy, Combination | 4 | 2021 | 1059 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 518 | 0.110 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2023 | 638 | 0.110 |
Why?
| | Phospholipases A | 4 | 1991 | 102 | 0.100 |
Why?
| | Ohio | 3 | 1999 | 154 | 0.100 |
Why?
| | Consensus | 1 | 2016 | 679 | 0.100 |
Why?
| | Type C Phospholipases | 2 | 1991 | 74 | 0.100 |
Why?
| | GTP-Binding Proteins | 1 | 1993 | 161 | 0.100 |
Why?
| | Animals | 18 | 2019 | 36768 | 0.100 |
Why?
| | Apoptosis | 1 | 2002 | 2548 | 0.100 |
Why?
| | Kidney Failure, Chronic | 1 | 1999 | 565 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 2 | 2010 | 916 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 679 | 0.100 |
Why?
| | Statistics, Nonparametric | 2 | 2006 | 430 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 1995 | 316 | 0.090 |
Why?
| | Activity Cycles | 1 | 1991 | 5 | 0.090 |
Why?
| | Aging | 3 | 2018 | 1861 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2013 | 2831 | 0.090 |
Why?
| | Age Distribution | 2 | 2005 | 391 | 0.090 |
Why?
| | Self Concept | 1 | 2013 | 252 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 768 | 0.090 |
Why?
| | Spinal Cord | 1 | 2014 | 369 | 0.090 |
Why?
| | Biomedical Research | 1 | 2018 | 689 | 0.090 |
Why?
| | Melitten | 1 | 1991 | 3 | 0.090 |
Why?
| | Infusions, Intravenous | 3 | 2017 | 408 | 0.090 |
Why?
| | Placenta | 4 | 1986 | 747 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2015 | 0.090 |
Why?
| | Biliary Atresia | 1 | 2012 | 163 | 0.090 |
Why?
| | Endocrinology | 2 | 2020 | 79 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1107 | 0.090 |
Why?
| | Brain | 2 | 2014 | 2669 | 0.090 |
Why?
| | Human Growth Hormone | 1 | 2010 | 45 | 0.090 |
Why?
| | Accreditation | 1 | 2010 | 83 | 0.090 |
Why?
| | Decision Trees | 1 | 2010 | 94 | 0.090 |
Why?
| | Cholesterol, HDL | 2 | 2008 | 203 | 0.090 |
Why?
| | Confidentiality | 1 | 2010 | 71 | 0.080 |
Why?
| | Brain Chemistry | 1 | 1990 | 118 | 0.080 |
Why?
| | Syndrome | 1 | 2011 | 357 | 0.080 |
Why?
| | Plasminogen | 2 | 2000 | 30 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 783 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3272 | 0.080 |
Why?
| | Models, Biological | 1 | 2017 | 1769 | 0.080 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 121 | 0.080 |
Why?
| | Gene Expression | 2 | 1995 | 1499 | 0.080 |
Why?
| | Diseases in Twins | 1 | 2010 | 175 | 0.080 |
Why?
| | Arcuate Nucleus of Hypothalamus | 3 | 1998 | 16 | 0.080 |
Why?
| | Acute Disease | 2 | 2007 | 1006 | 0.080 |
Why?
| | Time Factors | 2 | 2020 | 6792 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2005 | 3566 | 0.080 |
Why?
| | Fluid Therapy | 1 | 2010 | 147 | 0.080 |
Why?
| | Administration, Oral | 2 | 2021 | 808 | 0.080 |
Why?
| | Psychometrics | 1 | 2013 | 721 | 0.080 |
Why?
| | Sexual Maturation | 2 | 2019 | 55 | 0.080 |
Why?
| | Peptide Fragments | 3 | 2002 | 707 | 0.080 |
Why?
| | Phosphorylation | 2 | 2006 | 1756 | 0.080 |
Why?
| | Signal Transduction | 2 | 1993 | 5065 | 0.080 |
Why?
| | Trophoblasts | 3 | 1991 | 199 | 0.070 |
Why?
| | Autoimmunity | 1 | 2014 | 908 | 0.070 |
Why?
| | Lipids | 3 | 2010 | 665 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 7583 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2020 | 233 | 0.070 |
Why?
| | HeLa Cells | 2 | 2000 | 636 | 0.070 |
Why?
| | Phenotype | 3 | 2016 | 3199 | 0.070 |
Why?
| | Middle Aged | 3 | 2024 | 33200 | 0.070 |
Why?
| | Chronic Disease | 2 | 2007 | 1784 | 0.070 |
Why?
| | Ultrasonography | 2 | 2008 | 751 | 0.070 |
Why?
| | Sex Characteristics | 3 | 2019 | 763 | 0.070 |
Why?
| | Motor Activity | 2 | 2009 | 719 | 0.070 |
Why?
| | Exercise Tolerance | 1 | 2009 | 279 | 0.070 |
Why?
| | Transfection | 2 | 2000 | 945 | 0.070 |
Why?
| | Testis | 2 | 2018 | 150 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2009 | 184 | 0.070 |
Why?
| | Analysis of Variance | 2 | 2019 | 1318 | 0.060 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 258 | 0.060 |
Why?
| | Developing Countries | 1 | 2008 | 306 | 0.060 |
Why?
| | Adipose Tissue | 2 | 2021 | 629 | 0.060 |
Why?
| | Hypercholesterolemia | 1 | 2007 | 105 | 0.060 |
Why?
| | Thyroxine-Binding Proteins | 1 | 2006 | 3 | 0.060 |
Why?
| | Mandatory Testing | 1 | 2006 | 3 | 0.060 |
Why?
| | Carotid Artery Thrombosis | 1 | 2005 | 7 | 0.060 |
Why?
| | False Negative Reactions | 1 | 2006 | 53 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2006 | 43 | 0.060 |
Why?
| | Mucormycosis | 1 | 2005 | 22 | 0.060 |
Why?
| | Genetic Variation | 2 | 2023 | 985 | 0.060 |
Why?
| | Base Sequence | 4 | 1998 | 2180 | 0.060 |
Why?
| | Multiple Organ Failure | 1 | 2006 | 127 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2006 | 304 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2012 | 871 | 0.060 |
Why?
| | Arachidonic Acid | 5 | 1991 | 120 | 0.060 |
Why?
| | Exercise | 3 | 2008 | 2038 | 0.060 |
Why?
| | Appetite | 1 | 2005 | 69 | 0.060 |
Why?
| | Blotting, Western | 2 | 2000 | 1225 | 0.060 |
Why?
| | ROC Curve | 1 | 2006 | 545 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2014 | 1241 | 0.060 |
Why?
| | Molecular Sequence Data | 4 | 1998 | 2903 | 0.060 |
Why?
| | Hemodynamics | 1 | 2009 | 1110 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2000 | 813 | 0.060 |
Why?
| | Vomiting | 1 | 2005 | 129 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 1991 | 2603 | 0.060 |
Why?
| | Rats, Inbred Strains | 4 | 1991 | 361 | 0.050 |
Why?
| | HIV Infections | 1 | 1999 | 2812 | 0.050 |
Why?
| | Headache | 1 | 2005 | 151 | 0.050 |
Why?
| | Morbidity | 1 | 2005 | 322 | 0.050 |
Why?
| | Diet | 3 | 2008 | 1273 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 28 | 0.050 |
Why?
| | Chorionic Gonadotropin | 1 | 1983 | 80 | 0.050 |
Why?
| | Adiponectin | 2 | 2019 | 243 | 0.050 |
Why?
| | Linagliptin | 1 | 2023 | 5 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2023 | 52 | 0.050 |
Why?
| | Sinusitis | 1 | 2005 | 221 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2006 | 584 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2045 | 0.050 |
Why?
| | Linear Models | 2 | 2019 | 845 | 0.050 |
Why?
| | Glucagon | 1 | 2023 | 109 | 0.050 |
Why?
| | Sermorelin | 1 | 2002 | 1 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2002 | 41 | 0.050 |
Why?
| | Calcium | 2 | 1986 | 1197 | 0.050 |
Why?
| | Algorithms | 1 | 2010 | 1686 | 0.050 |
Why?
| | Quality of Life | 2 | 2011 | 2868 | 0.050 |
Why?
| | Estradiol | 2 | 2019 | 518 | 0.050 |
Why?
| | Culture | 1 | 2003 | 127 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2022 | 154 | 0.050 |
Why?
| | Surveys and Questionnaires | 3 | 2020 | 5749 | 0.050 |
Why?
| | Off-Label Use | 1 | 2022 | 52 | 0.050 |
Why?
| | Risk Assessment | 2 | 2022 | 3429 | 0.050 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.050 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.050 |
Why?
| | Ventromedial Hypothalamic Nucleus | 2 | 1991 | 6 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1942 | 0.050 |
Why?
| | Protein S | 1 | 2001 | 9 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 197 | 0.040 |
Why?
| | Antithrombin III | 1 | 2001 | 13 | 0.040 |
Why?
| | Prothrombin | 1 | 2001 | 26 | 0.040 |
Why?
| | Prothrombin Time | 1 | 2001 | 35 | 0.040 |
Why?
| | Calcitonin | 1 | 2001 | 27 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2001 | 57 | 0.040 |
Why?
| | Diabetic Nephropathies | 1 | 2024 | 293 | 0.040 |
Why?
| | Bone Development | 1 | 2001 | 54 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2012 | 2624 | 0.040 |
Why?
| | Cephalometry | 1 | 2000 | 33 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2001 | 86 | 0.040 |
Why?
| | Expert Testimony | 1 | 2020 | 39 | 0.040 |
Why?
| | Protein C | 1 | 2001 | 59 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 953 | 0.040 |
Why?
| | Conjunctiva | 1 | 2000 | 51 | 0.040 |
Why?
| | Conjunctivitis | 1 | 2000 | 30 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2000 | 75 | 0.040 |
Why?
| | Bleeding Time | 1 | 1999 | 7 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 2001 | 111 | 0.040 |
Why?
| | Fibrinogen | 1 | 2001 | 168 | 0.040 |
Why?
| | Language | 1 | 2003 | 296 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 134 | 0.040 |
Why?
| | Epidermal Growth Factor | 1 | 2000 | 174 | 0.040 |
Why?
| | Polyuria | 1 | 1999 | 2 | 0.040 |
Why?
| | Thirst | 1 | 1999 | 5 | 0.040 |
Why?
| | Octreotide | 1 | 1999 | 26 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2019 | 59 | 0.040 |
Why?
| | Acanthosis Nigricans | 1 | 1999 | 6 | 0.040 |
Why?
| | Phospholipases A2 | 3 | 1991 | 80 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 614 | 0.040 |
Why?
| | Testicular Hormones | 1 | 2018 | 9 | 0.040 |
Why?
| | Hormones | 1 | 1999 | 142 | 0.040 |
Why?
| | Inositol | 2 | 1991 | 26 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2005 | 1055 | 0.040 |
Why?
| | Reproductive Health | 1 | 2019 | 91 | 0.040 |
Why?
| | COS Cells | 1 | 1998 | 188 | 0.040 |
Why?
| | Menarche | 1 | 2018 | 60 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1998 | 269 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 3 | 1998 | 2481 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2473 | 0.040 |
Why?
| | Receptors, Somatostatin | 1 | 1998 | 25 | 0.040 |
Why?
| | Hydrolysis | 2 | 1991 | 191 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3399 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 548 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1019 | 0.040 |
Why?
| | Cyclic AMP | 1 | 1998 | 234 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 520 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 139 | 0.040 |
Why?
| | Blood Coagulation Disorders | 1 | 1999 | 173 | 0.040 |
Why?
| | DNA Primers | 1 | 1998 | 513 | 0.030 |
Why?
| | Kinetics | 2 | 2000 | 1668 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 57 | 0.030 |
Why?
| | Health Education | 1 | 2000 | 337 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 128 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 1998 | 2145 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 1999 | 152 | 0.030 |
Why?
| | Cholesterol, LDL | 2 | 2009 | 366 | 0.030 |
Why?
| | Alternative Splicing | 1 | 1998 | 227 | 0.030 |
Why?
| | Sertoli Cells | 1 | 2016 | 26 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2017 | 194 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2000 | 838 | 0.030 |
Why?
| | Postprandial Period | 1 | 2017 | 107 | 0.030 |
Why?
| | Inhibins | 1 | 2016 | 44 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 497 | 0.030 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.030 |
Why?
| | Speech Disorders | 1 | 2016 | 34 | 0.030 |
Why?
| | Anti-Mullerian Hormone | 1 | 2016 | 57 | 0.030 |
Why?
| | Oxygen Consumption | 2 | 2009 | 696 | 0.030 |
Why?
| | Truth Disclosure | 1 | 2016 | 46 | 0.030 |
Why?
| | Pituitary Gland, Anterior | 1 | 1996 | 38 | 0.030 |
Why?
| | Language Development Disorders | 1 | 2016 | 46 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 4 | 1 | 1995 | 4 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 313 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 87 | 0.030 |
Why?
| | Genes, Homeobox | 1 | 1996 | 50 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 1996 | 96 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2016 | 76 | 0.030 |
Why?
| | Mosaicism | 1 | 2016 | 73 | 0.030 |
Why?
| | Luteinizing Hormone | 1 | 2016 | 185 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 533 | 0.030 |
Why?
| | Embryo Implantation | 1 | 1995 | 30 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 271 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2020 | 520 | 0.030 |
Why?
| | Cost of Illness | 1 | 2018 | 300 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1986 | 1089 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 344 | 0.030 |
Why?
| | Follicle Stimulating Hormone | 1 | 2016 | 244 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 418 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 143 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2677 | 0.030 |
Why?
| | Prostaglandins E | 3 | 1991 | 47 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2019 | 2999 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1697 | 0.030 |
Why?
| | Cell Line | 1 | 2000 | 2836 | 0.030 |
Why?
| | Uterus | 1 | 1995 | 215 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 1996 | 856 | 0.030 |
Why?
| | Mental Disorders | 1 | 2003 | 1075 | 0.030 |
Why?
| | Adenosine Diphosphate Ribose | 1 | 1993 | 7 | 0.030 |
Why?
| | Cholera Toxin | 1 | 1993 | 32 | 0.030 |
Why?
| | Child Development | 1 | 1999 | 471 | 0.030 |
Why?
| | Rats, Inbred Lew | 1 | 1993 | 114 | 0.030 |
Why?
| | Feeding Behavior | 1 | 1999 | 648 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1619 | 0.030 |
Why?
| | Molecular Probes | 1 | 1993 | 36 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 1993 | 1059 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2016 | 264 | 0.030 |
Why?
| | Dwarfism, Pituitary | 1 | 1993 | 3 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 657 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2019 | 803 | 0.030 |
Why?
| | Observer Variation | 1 | 2014 | 345 | 0.030 |
Why?
| | Decidua | 2 | 1983 | 24 | 0.020 |
Why?
| | Prolactin | 2 | 1983 | 97 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1434 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 1996 | 504 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 328 | 0.020 |
Why?
| | Steroids | 1 | 2012 | 167 | 0.020 |
Why?
| | Neurons | 2 | 1990 | 1583 | 0.020 |
Why?
| | Radiography | 1 | 2014 | 829 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2012 | 267 | 0.020 |
Why?
| | Cysteamine | 1 | 1990 | 8 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2010 | 79 | 0.020 |
Why?
| | Dasatinib | 1 | 2010 | 54 | 0.020 |
Why?
| | Dihydrotestosterone | 1 | 1990 | 44 | 0.020 |
Why?
| | Orchiectomy | 1 | 1990 | 71 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 190 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1063 | 0.020 |
Why?
| | Benzamides | 1 | 2010 | 217 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2009 | 44 | 0.020 |
Why?
| | Models, Neurological | 1 | 1991 | 243 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Plethysmography | 1 | 2009 | 106 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 241 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1768 | 0.020 |
Why?
| | Pancreatic Diseases | 1 | 2009 | 72 | 0.020 |
Why?
| | South Carolina | 1 | 2008 | 39 | 0.020 |
Why?
| | Thinness | 1 | 2009 | 91 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1319 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 1999 | 4279 | 0.020 |
Why?
| | DNA | 3 | 1993 | 1458 | 0.020 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2009 | 159 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 130 | 0.020 |
Why?
| | Piperazines | 1 | 2010 | 350 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2008 | 90 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 1991 | 434 | 0.020 |
Why?
| | Mice | 4 | 2019 | 17731 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 412 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2060 | 0.020 |
Why?
| | Pyrimidines | 1 | 2010 | 470 | 0.020 |
Why?
| | Fractures, Spontaneous | 1 | 2007 | 15 | 0.020 |
Why?
| | Asthma | 1 | 2000 | 2290 | 0.020 |
Why?
| | Phorbol Esters | 1 | 1986 | 14 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 411 | 0.020 |
Why?
| | Calcium, Dietary | 1 | 2007 | 57 | 0.020 |
Why?
| | Glycerides | 1 | 1986 | 21 | 0.020 |
Why?
| | Diglycerides | 1 | 1986 | 61 | 0.020 |
Why?
| | Calcium Radioisotopes | 1 | 1986 | 2 | 0.020 |
Why?
| | Calcimycin | 1 | 1986 | 49 | 0.020 |
Why?
| | Bone Density Conservation Agents | 1 | 2007 | 80 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 625 | 0.020 |
Why?
| | Mucor | 1 | 2005 | 7 | 0.020 |
Why?
| | Echocardiography | 1 | 2009 | 659 | 0.020 |
Why?
| | Telencephalon | 1 | 2005 | 16 | 0.020 |
Why?
| | Tritium | 1 | 1985 | 76 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 1024 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2005 | 19 | 0.020 |
Why?
| | Homeostasis | 1 | 2009 | 618 | 0.020 |
Why?
| | Vitamins | 1 | 2007 | 177 | 0.010 |
Why?
| | Urban Population | 1 | 2008 | 472 | 0.010 |
Why?
| | Heart Rate | 1 | 2009 | 823 | 0.010 |
Why?
| | Orbit | 1 | 2005 | 70 | 0.010 |
Why?
| | Osteogenesis | 1 | 2007 | 187 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1986 | 260 | 0.010 |
Why?
| | Paranasal Sinuses | 1 | 2005 | 80 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2009 | 778 | 0.010 |
Why?
| | Patient Selection | 1 | 2008 | 689 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2008 | 459 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 1995 | 1902 | 0.010 |
Why?
| | Bucladesine | 1 | 1983 | 26 | 0.010 |
Why?
| | Vitamin D | 1 | 2007 | 395 | 0.010 |
Why?
| | Aged | 1 | 2003 | 23729 | 0.010 |
Why?
| | Primary Health Care | 1 | 2013 | 1714 | 0.010 |
Why?
| | Mutation | 1 | 1993 | 3953 | 0.010 |
Why?
| | Cushing Syndrome | 1 | 2000 | 10 | 0.010 |
Why?
| | Superinfection | 1 | 2000 | 6 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1938 | 0.010 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2000 | 11 | 0.010 |
Why?
| | Growth | 1 | 2000 | 60 | 0.010 |
Why?
| | Adrenal Glands | 1 | 2000 | 77 | 0.010 |
Why?
| | Eye Infections, Bacterial | 1 | 2000 | 28 | 0.010 |
Why?
| | Pneumococcal Infections | 1 | 2000 | 115 | 0.010 |
Why?
| | Cells, Cultured | 2 | 1983 | 4194 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 2000 | 169 | 0.010 |
Why?
| | Inflammation | 1 | 2009 | 2834 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1996 | 27 | 0.010 |
Why?
| | Pituitary Hormones | 1 | 1996 | 16 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 170 | 0.010 |
Why?
| | Genes | 1 | 1996 | 230 | 0.010 |
Why?
| | Endometrium | 1 | 1995 | 58 | 0.010 |
Why?
| | Stromal Cells | 1 | 1995 | 111 | 0.010 |
Why?
| | Myometrium | 1 | 1995 | 39 | 0.010 |
Why?
| | Glycosylation | 1 | 1995 | 163 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1995 | 315 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1995 | 329 | 0.010 |
Why?
| | Hematopoiesis | 1 | 1996 | 190 | 0.010 |
Why?
| | Epithelium | 1 | 1995 | 311 | 0.010 |
Why?
| | Animals, Newborn | 1 | 1996 | 843 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1993 | 137 | 0.010 |
Why?
| | Gestational Age | 1 | 1995 | 902 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1993 | 523 | 0.010 |
Why?
| | Saccharomyces cerevisiae | 1 | 1996 | 558 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 173 | 0.010 |
Why?
| | Drug Interactions | 1 | 1990 | 405 | 0.000 |
Why?
| | DNA-Binding Proteins | 1 | 1996 | 1500 | 0.000 |
Why?
| | Transcription Factors | 1 | 1996 | 1714 | 0.000 |
Why?
| | Cycloheximide | 1 | 1986 | 55 | 0.000 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1986 | 150 | 0.000 |
Why?
| | Immunohistochemistry | 1 | 1990 | 1731 | 0.000 |
Why?
| | Proteins | 2 | 1983 | 1009 | 0.000 |
Why?
| | Methionine | 1 | 1986 | 159 | 0.000 |
Why?
| | Centrifugation, Isopycnic | 1 | 1983 | 1 | 0.000 |
Why?
| | Microbial Collagenase | 1 | 1983 | 12 | 0.000 |
Why?
| | Hyaluronoglucosaminidase | 1 | 1983 | 8 | 0.000 |
Why?
| | Fluorescent Antibody Technique | 1 | 1983 | 386 | 0.000 |
Why?
| | Flufenamic Acid | 1 | 1981 | 3 | 0.000 |
Why?
| | Cell Separation | 1 | 1983 | 318 | 0.000 |
Why?
| | Prostaglandins F | 1 | 1981 | 17 | 0.000 |
Why?
| | Stimulation, Chemical | 1 | 1981 | 59 | 0.000 |
Why?
| | Deoxycholic Acid | 1 | 1981 | 14 | 0.000 |
Why?
| | Indomethacin | 1 | 1981 | 81 | 0.000 |
Why?
| | Dinoprost | 1 | 1981 | 44 | 0.000 |
Why?
|
|
Zeitler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|